MA40814A1 - Compositions pharmaceutiques pour thérapie combinée - Google Patents

Compositions pharmaceutiques pour thérapie combinée

Info

Publication number
MA40814A1
MA40814A1 MA40814A MA40814A MA40814A1 MA 40814 A1 MA40814 A1 MA 40814A1 MA 40814 A MA40814 A MA 40814A MA 40814 A MA40814 A MA 40814A MA 40814 A1 MA40814 A1 MA 40814A1
Authority
MA
Morocco
Prior art keywords
agonist
ppar
pharmaceutical compositions
combination therapy
combination
Prior art date
Application number
MA40814A
Other languages
English (en)
Inventor
Mark Pruzanski
Luciano Adorini
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56564878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40814(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MA40814A1 publication Critical patent/MA40814A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant une combinaison d'un agoniste de fxr et au moins un agent réducteur de lipides (par exemple, agoniste de ppar-alpha agoniste de ppar-delta, agoniste de ppar-alpha et double delta et/ou statine). La présente invention concerne également l'utilisation de la combinaison pour le traitement ou la prévention d'une maladie ou affection à médiation par fxr, telle que la cirrhose biliaire primitive (pbc), la cholangite sclérosante primitive (
MA40814A 2015-02-06 2016-02-05 Compositions pharmaceutiques pour thérapie combinée MA40814A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562113134P 2015-02-06 2015-02-06
PCT/US2016/016694 WO2016127019A2 (fr) 2015-02-06 2016-02-05 Compositions pharmaceutiques pour thérapie combinée

Publications (1)

Publication Number Publication Date
MA40814A1 true MA40814A1 (fr) 2019-08-30

Family

ID=56564878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40814A MA40814A1 (fr) 2015-02-06 2016-02-05 Compositions pharmaceutiques pour thérapie combinée

Country Status (30)

Country Link
US (5) US11311557B2 (fr)
EP (2) EP4035665A1 (fr)
JP (2) JP7306791B2 (fr)
KR (1) KR20170115071A (fr)
CN (1) CN107405325B (fr)
AR (1) AR103624A1 (fr)
AU (2) AU2016215179B2 (fr)
BR (1) BR112017016766B1 (fr)
CA (1) CA2976056C (fr)
CL (3) CL2017001983A1 (fr)
CO (1) CO2017007959A2 (fr)
CR (1) CR20170356A (fr)
DK (1) DK3253382T3 (fr)
EA (1) EA036404B1 (fr)
EC (1) ECSP17057848A (fr)
ES (1) ES2905872T3 (fr)
GT (1) GT201700174A (fr)
IL (2) IL253719B (fr)
MA (1) MA40814A1 (fr)
MX (1) MX388508B (fr)
NI (1) NI201700100A (fr)
PE (1) PE20180027A1 (fr)
PH (1) PH12017501384A1 (fr)
SG (1) SG11201706347SA (fr)
SV (1) SV2017005512A (fr)
TN (1) TN2017000344A1 (fr)
TW (1) TW201628625A (fr)
UA (1) UA125744C2 (fr)
WO (1) WO2016127019A2 (fr)
ZA (1) ZA201706007B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103624A1 (es) 2015-02-06 2017-05-24 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia de combinación
CA2981507A1 (fr) 2015-04-07 2016-10-13 Intercept Pharmaceuticals, Inc. Compositions pharmaceutiques pour therapie combinee
HK1254057A1 (zh) * 2015-09-24 2019-07-12 英特塞普特医药品公司 用於制备胆汁酸衍生物的方法和中间体
CN114796237B (zh) * 2016-03-31 2024-02-23 基恩菲特公司 胆汁淤积性疾病的治疗方法
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US11331292B2 (en) 2016-03-31 2022-05-17 Genfit Methods of treatment of cholestatic diseases
WO2018104916A1 (fr) * 2016-12-09 2018-06-14 Cadila Healthcare Limited Traitement de la cholangite biliaire primitive
AU2018223146B2 (en) * 2017-02-21 2023-12-21 Genfit Combination of a PPAR agonist with a FXR agonist
US20200276178A1 (en) * 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US12458612B2 (en) * 2019-04-10 2025-11-04 Genfit Combination therapy comprising compounds of formula (I) and GLP-1 receptor agonists
EA202193334A1 (ru) * 2019-05-30 2022-03-14 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции, содержащие агонист fxr и фибрат, для применения при лечении холестатического заболевания печени
CN110287493B (zh) * 2019-06-28 2023-04-18 中国科学技术信息研究所 风险短语识别方法、装置、电子设备及存储介质
AU2020312735A1 (en) * 2019-07-18 2021-12-16 Enyo Pharma Method for decreasing adverse-effects of interferon
CN114727976A (zh) * 2019-09-20 2022-07-08 雷内奥制药公司 PPAR-δ激动剂在肾脏疾病治疗中的用途
EP4061357A4 (fr) * 2019-11-22 2024-01-10 Avolynt Utilisation d'inhibiteurs de sglt2 pour traiter la cholangite biliaire primitive
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
CN112885471B (zh) * 2021-03-12 2023-01-24 上海中医药大学附属岳阳中西医结合医院 基于贝叶斯网络最大熵自学习扩展集对分析的银屑病疗效评价系统
US20250161326A1 (en) * 2022-01-28 2025-05-22 Intercept Pharmaceuticals, Inc. Combination therapy
WO2024132001A1 (fr) * 2022-12-21 2024-06-27 Charles University, Faculty Of Pharmacy In Hradec Kralove Ligands de récepteurs nucléaires multicibles à base d'acide 2-(4-(quinolin-2-yloxy)phénoxy)propanoïque et d'acide 2-(4-(quinoxalin-2-yloxy)phénoxy)propanoïque pour le traitement de maladies métaboliques et hépatiques
WO2025250918A1 (fr) * 2024-05-30 2025-12-04 Intercept Pharmaceuticals, Inc. Nouvelles compositions

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3262580A (en) 1964-06-23 1966-07-26 Mcdowell Wellman Eng Co Slewable gantry crane
FR1498459A (fr) 1965-07-30 1968-01-08
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
US3716583A (en) 1969-04-16 1973-02-13 Sumitomo Chemical Co Phenoxy carboxylic acid derivative
AT296986B (de) 1969-08-13 1972-03-10 Merz & Co Verfahren zur Herstellung von neuen α-Halogenphenoxy-isobutyroyl-β-nicotinoyl-glykolen
DE2230383C3 (de) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
JPS5118954B2 (fr) 1972-02-04 1976-06-14
US3948973A (en) 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
DE2308826C3 (de) 1973-02-22 1980-03-27 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Phenoxyalkancarbonsäureester von Oxyalkyltheophyllinen, Verfahren zu ihrer Herstellung und Arzneimittel
FR2244511B1 (fr) 1973-07-05 1977-07-15 Roussel Uclaf
ES488665A0 (es) 1980-02-15 1980-12-16 Especialidades Farmaco Terape Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
DE69329894T2 (de) 1992-12-08 2001-05-03 Ss Pharmaceutical Co., Ltd. Arylamidderivate
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
PL334840A1 (en) 1997-01-24 2000-03-27 Univ California Application of fxr, pparalpha and lxralpha activators in order to restore the barrier function, to stimulate epithelium differentation and to inhibit proliferation
SK1392000A3 (en) * 1997-08-29 2000-08-14 Pfizer Prod Inc Combination therapy comprising amlodipine and a statin compound
PL193086B1 (pl) 1997-10-27 2007-01-31 Reddys Lab Ltd Dr Nowe związki tricykliczne i związki pośrednie, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
JP2002532539A (ja) 1998-12-18 2002-10-02 アボット・ラボラトリーズ 脂質調節剤を含む新規な製剤
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
US6465258B1 (en) 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism
US6071955A (en) * 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
WO2001080852A1 (fr) 2000-04-19 2001-11-01 Borody Thomas J Compositions et methodes pour traiter des troubles associes a l'hyperlipidemie
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
ATE283253T1 (de) 2000-09-18 2004-12-15 Glaxo Group Ltd Substituierte aminopropoxyarylderivate als lxr agonisten
EP1392714B1 (fr) 2001-03-12 2005-08-31 Intercept Pharmaceuticals, Inc. Steroides comme agonistes de fxr
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1568706A1 (fr) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Nouveau agonist steroidal pour FXR
GB0405349D0 (en) 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
US9498484B2 (en) 2004-03-12 2016-11-22 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
EP1877373A2 (fr) 2005-05-05 2008-01-16 Microbia, Inc. Inhibiteurs d'absorption de biphenylazetidinone cholesterol
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
EP1987051A2 (fr) 2006-02-14 2008-11-05 Intercept Pharmaceuticals, Inc. Derives d'acides biliaires en tant que ligands de fxr pour la prevention ou le traitement de maladies ou d'etats induits par fxr
US20070197606A1 (en) 2006-02-22 2007-08-23 Burczynski Frank J Use of ppar agonists as anti-oxidants
EP2001484A4 (fr) * 2006-03-22 2010-04-21 Harvard College Méthodes et compositions destinées à traiter l'hypercholestérolémie et l'athérosclérose
EA015632B9 (ru) 2006-05-24 2012-08-30 Эли Лилли Энд Компани Агонисты fxr
DE602007005256D1 (de) 2006-05-24 2010-04-22 Lilly Co Eli Verbindungen und verfahren zur modulierung von fx-rezeptoren
DK2040713T3 (da) * 2006-06-27 2014-09-29 Intercept Pharmaceuticals Inc Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
WO2008015763A1 (fr) 2006-08-04 2008-02-07 Aska Pharmaceutical Co., Ltd. Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire
EP1886685A1 (fr) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
EP1894928A1 (fr) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Composes heterocycliques de liaison au fxr
EP1894924A1 (fr) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Composés hétérocycliques de liason du FXR
WO2008039829A2 (fr) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Inhibiteurs de l'absorption de cholestérol de diphénylhétérocycle
CL2007003035A1 (es) * 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (fr) 2008-04-18 2009-10-21 Merck Sante Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR
EP2289883A1 (fr) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Nouveaux composés modulant l'activité du recepteur FXR (NR1H4)
TR201810393T4 (tr) * 2009-11-26 2018-08-27 Genfit Karaciğer rahatıszlıklarının tedavisi için 1,3-difenilprop-2-en-1-on türevlerinin kullanımı.
SG10201607230SA (en) 2012-06-19 2016-10-28 Intercept Pharmaceuticals Inc Preparation, Uses And Solid Forms Of Obeticholic Acid
BR112015009395A2 (pt) 2012-10-26 2017-07-04 Intercept Pharmaceuticals Inc processo para preparação de derivados do ácido biliar
DK2997035T3 (en) 2013-05-14 2018-07-02 Intercept Pharmaceuticals Inc 11-HYDROXY-6-SUBSTITUTED BALIC ACID DERIVATIVES AND AMINO ACID CONJUGATES THEREOF AS FARNESOID X RECEPTOR MODULATORS
US10077268B2 (en) * 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
AR103624A1 (es) 2015-02-06 2017-05-24 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia de combinación
EA202193334A1 (ru) 2019-05-30 2022-03-14 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции, содержащие агонист fxr и фибрат, для применения при лечении холестатического заболевания печени

Also Published As

Publication number Publication date
EP3253382A4 (fr) 2018-10-31
DK3253382T3 (da) 2022-02-14
CN107405325A (zh) 2017-11-28
CN107405325B (zh) 2021-11-12
US20250367216A1 (en) 2025-12-04
IL290823A (en) 2022-04-01
JP2022000483A (ja) 2022-01-04
SG11201706347SA (en) 2017-09-28
US12337003B2 (en) 2025-06-24
US20220280533A1 (en) 2022-09-08
IL253719A0 (en) 2017-09-28
CL2018003604A1 (es) 2019-02-22
SV2017005512A (es) 2018-06-12
CO2017007959A2 (es) 2017-10-31
MX2017010131A (es) 2017-11-01
AU2016215179B2 (en) 2021-02-25
BR112017016766A2 (pt) 2018-04-10
US20180008616A1 (en) 2018-01-11
NI201700100A (es) 2018-09-06
ECSP17057848A (es) 2017-10-31
MX388508B (es) 2025-03-20
CA2976056A1 (fr) 2016-08-11
EA036404B1 (ru) 2020-11-06
US20250367217A1 (en) 2025-12-04
IL253719B (en) 2022-04-01
CR20170356A (es) 2018-02-28
GT201700174A (es) 2018-11-13
JP7306791B2 (ja) 2023-07-11
TW201628625A (zh) 2016-08-16
EP3253382A2 (fr) 2017-12-13
EP3253382B1 (fr) 2021-11-17
ES2905872T3 (es) 2022-04-12
AU2016215179A1 (en) 2017-08-24
US11311557B2 (en) 2022-04-26
AR103624A1 (es) 2017-05-24
BR112017016766B1 (pt) 2023-11-07
UA125744C2 (uk) 2022-06-01
CL2017001983A1 (es) 2018-04-20
ZA201706007B (en) 2019-01-30
PH12017501384A1 (en) 2018-01-08
HK1246191A1 (zh) 2018-09-07
KR20170115071A (ko) 2017-10-16
WO2016127019A3 (fr) 2016-11-03
CA2976056C (fr) 2024-02-06
US20220280534A1 (en) 2022-09-08
WO2016127019A2 (fr) 2016-08-11
EA201791770A1 (ru) 2017-12-29
CL2018001006A1 (es) 2018-06-15
TN2017000344A1 (en) 2019-01-16
EP4035665A1 (fr) 2022-08-03
JP2018504438A (ja) 2018-02-15
AU2021201015A1 (en) 2021-03-11
PE20180027A1 (es) 2018-01-09

Similar Documents

Publication Publication Date Title
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA46990B1 (fr) Compositions glp-1 et ses utilisations
WO2020106647A3 (fr) Polythérapie comprenant un inhibiteur de krasg12c et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA57908B1 (fr) Composés macrocycliques substitués et méthodes de traitement associées
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA40290A1 (fr) Agents immunorégulateurs
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
EP4008718A4 (fr) Dérivé d'hétéroarylamidopyridinol et composition pharmaceutique le comprenant en tant que principe actif pour prévenir ou traiter une maladie auto-immune
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
MA53010B1 (fr) Formulations d'un inhibiteur de axl/mer
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
WO2019032528A8 (fr) Inhibiteurs bicycliques d'histone désacétylase
MA38699A1 (fr) Formulation orale pour le traitement de maladies cardiovasculaires
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EP4023232A4 (fr) Composition pharmaceutique pour le traitement du cancer comprenant un virus anticancéreux, un inhibiteur de point de contrôle immunitaire et une hydroxyurée en tant que principes actifs
EP3741366A4 (fr) Composition pharmaceutique comprenant une dunnione à titre de principe actif pour la prévention ou le traitement de la perte de cheveux
MA61742A1 (fr) Composition pharmaceutique aqueuse d'anticorps anti pd-1 prolgolimab et son utilisation
MA45609B1 (fr) Compositions d'acide cromoglicique pour le traitement de la dermatite
BR112018003392A2 (pt) composição farmacêutica compreendendo um inibidor da hmg-coa redutase e um inibidor eca
MA34975B1 (fr) Composition d'inhibiteur viral pour une utilisation therapeutique in vivo.
FR3058060B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.